Navigation Links
RBC Life Sciences Reports Second Quarter 2011 Results

IRVING, Texas, Aug. 11, 2011 /PRNewswire/ -- (RBC Life Sciences: OTCQB: RBCL) - RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported consolidated net sales of $7.5 million for the quarter ended June 30, 2011, compared to net sales of $7.8 million for the same period during 2010.  The Company also reported net earnings of $17,000, or $0.00 per share, compared to net earnings of $172,000, or $0.01 per share, for the same quarter last year.  Net sales were $14.0 million and $14.8 million for the six months ended June 30, 2011 and 2010, respectively, while net earnings were $160,000 and $383,000 for the six months ended June 30, 2011 and 2010, respectively.

"Due to a variety of logistical factors and weakness in some international markets, net sales in our largest revenue channel declined during the first six months of 2011 resulting in an overall decline in consolidated net sales and net earnings," said RBC Life Sciences President and CEO, Clinton H. Howard. "However, we continue to see growth in Associate network sales, which increased 57% during the first six months of 2011.  Sales growth in this channel accelerated during the second quarter following the introduction in May of our exciting new product, Stem-Kine™."

Stem-Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem-cell-producing tissues to increase their production of stem cells, which form the natural repair and renewal system of the body.  The Company distributes Stem-Kine under an exclusive license agreement that covers the U.S. and 41 other countries.

About RBC Life SciencesThrough wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.RBC Life Sciences, Inc.Summary Results of Operations(in thousands, except per share data)(unaudited)Quarters Ended June 30,20112010Net sales



7,838Gross profit

3,9853,656Operating profit

57357Earnings before income taxes

22318Provision for income taxes

5146Net earnings

17172Earnings per share - basic



0.01Earnings per share - diluted


0.000.01Weighted average shares outstanding - basic

22,22921,922Weighted average shares outstanding - diluted

22,54822,387Six Months Ended June 30,20112010Net sales

14,03214,820Gross profit

7,3017,045Operating profit

319757Earnings before income taxes

247679Provision for income taxes

87296Net earnings

160383Earnings per share - basic



0.02Earnings per share - diluted



0.02Weighted average shares outstanding - basic

22,22921,922Weighted average shares outstanding - diluted

22,54722,322RBC Life Sciences, Inc.Condensed Consolidated Balance Sheets(in thousands)(unaudited)June 30,December 31,20112010AssetsCash and cash equivalents




5,5485,343Other current assets

2,1561,696Total current assets

13,31811,259Other assets

6,9327,085Total assets



18,344Liabilities and shareholders' equityAccounts payable and accrued liabilities



3,087Deferred revenue

3,5732,490Other current liabilities

175168Total current liabilities

7,5595,745Other liabilities

2,6362,723Shareholders' equity

10,0559,876Total liabilities and shareholders' equity




SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
2. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
3. Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
6. Cardica to Present at the Wedbush Life Sciences Management Access Conference
7. Caliper Life Sciences Reports Second Quarter 2011 Results
8. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
9. Caliper Life Sciences to Present at the Leerink Swann Life Science Tools & Diagnostics Roundtable
10. Caliper Life Sciences Second Quarter Results Conference Call Notice
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, ... solutions that aid in the early detection and intervention ... awarded Vigilant,s founder and CEO, Matthew H.J. Kim ... Award, which recognizes an entrepreneur who has made extraordinary ... life sciences industry in the leadership of a ...
(Date:10/13/2015)... , Oct. 13, 2015   ... first-ever direct-to-consumer laboratory home testing kit for ... digital technologies provide an unparalleled, detailed assessment ... breast milk—fats, proteins, carbs and key vitamins—all ... portal for personal health tracking.  In addition, Happy ...
(Date:10/13/2015)... , October 13, 2015 ... announced the appointment of Harry Lander , PhD as ... Company,s Chairman & CEO David Koos as Regen ... molecule and immuno-oncological therapeutics. --> Regen BioPharma, ... appointment of Harry Lander , PhD as its new ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... “Women have 2 questions when they ... to live?’ The second is, “Will I lose my hair?’” , Carly Klein is ... women with licensed medical professionals to develop personalized hair loss treatment plans. With 10 ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of guides ... sexual assault and other trauma. The toolkit, funded by the U.S. Department of Education, ... 21st anniversary. , AIR developed the Safe Place toolkit in ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... , ... October 13, 2015 , ... According to an ... recent study has shown that women who successfully lose weight with a bariatric procedure ... United States each year. The article notes that anywhere from 40 to 50 percent ...
Breaking Medicine News(10 mins):